Abstract
EGFR(C797S) mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clinical need" for nonsmall cell lung cancer patients. The pyrimidopyrimidinone derivative JND3229 was identified as a new highly potent EGFR(C797S) inhibitor with single digit nM potency. It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR(19D/T790M/C797S) cells. A high-resolution X-ray crystallographic structure was also determined to elucidate the interactions between JND3229 and EGFR(T790M/C797S). Our study provides an important structural and chemical basis for future development of new generation EGFR(C797S) inhibitors as anticancer drugs.